Lexaria Enters Into Material Transfer Agreement for DehydraTECH Research

KELOWNA, BC / ACCESSWIRE / September 3, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has entered into a material transfer agreement with a pharmaceutical company (“PharmaCO”) to evaluate Lexaria’s DehydraTECH^TM technology in a preclinical setting.

Under the terms of the agreement, Lexaria will be responsible for the formulation and supply of certain DehydraTECH compositions. The pharmacokinetics of DehydraTECH compositions will be evaluated in animal studies. Lexaria has granted PharmaCO a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under investigation. The work is expected to be completed in approximately 6 months or less.